TSX gains after CPI shows US inflation rose 3%
Investing.com - TD Cowen has raised its price target on UCB (BR:UCB) (OTC:UCBJY) stock to EUR300.00 from EUR255.00 while maintaining a Buy rating on the Belgian pharmaceutical company.
The firm cited strong adoption trends for UCB’s Bimzelx treatment, which is approved for conditions including psoriasis, psoriatic arthritis, and hidradenitis suppurativa (HS).
TD Cowen noted "scarcity value" for UCB given the company’s clear visibility into value drivers with "accelerating" and "durable" earnings potential compared to industry peers.
The analyst’s decision to increase the price target was specifically influenced by IQVIA prescription trends and higher survey expectations for Bimzelx adoption, leading to upward revisions in near-term sales projections.
The new price target of EUR300 represents approximately 20-21 times TD Cowen’s earnings estimate for UCB in 2027, with the firm indicating there is still "significant long-term upside" potential beyond this valuation.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.